Proprietary drug names meeting
This article was originally published in The Tan Sheet
Executive Summary
Public meeting on "Minimizing Medication Errors - Methods for Evaluating Proprietary Names for Their Confusion Potential" will be held June 26 by FDA, PhRMA, Institute for Safe Medication Practices (ISMP), according to 1May 30 Federal Register notice. Goal of meeting is to solicit views on FDA recommendation that drug manufacturers "perform proprietary name testing prior to submitting NDAs and ANDAs," agency says. Input from workshop, other comments "may be considered in developing a draft guidance on this topic," FDA adds...